Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Bimekizumab demonstrated sustained efficacy in treating axial spondyloarthritis (axSpA) up to week 52, with a safety profile consistent with previous observations, according to phase 3 data published in Annals of the Rheumatic Diseases.1
"Dual inhibition of IL-17A and IL-17F with subcutaneous [bimekizumab] 160 mg [every 4 weeks] led to clinically meaningful improvements in a range of efficacy outcomes, across the full disease spectrum of axSpA to week 52," investigators wrote.
The 52-week randomized controlled trials BE MOBILE 1 and BE MOBILE 2 aimed to assess the long-term efficacy of bimekizumab (Assessment of Spondyloarthritis International Society ≥ 40% improvement; ASAS40) across various clinical response criteria, disease activity measures, patient-reported outcomes, and peripheral manifestations.
Patients switching from placebo to bimekizumab at week 16 exhibited comparable improvements by week 52 to those initially assigned the intervention group. Investigators noted the safety profile observed throughout the study remained consistent with previous data.
Axial spondyloarthritis encompasses both non-radiographic (nr-) and radiographic (r-) forms of the condition and is characterized by inflammation primarily in the spine and sacroiliac joints. Bimekizumab is a monoclonal IgG1 antibody that targets IL17F and IL17A and has exhibited long-term treatment reliability in psoriatic arthritis, another inflammatory rheumatic disease.2
The research, comprising BE MOBILE 1 (for nr-axSpA) and BE MOBILE 2 (for r-axSpA), included a 16-week, double-blind, placebo-controlled phase followed by a 36-week maintenance period. Subsequently, all patients received subcutaneous bimekizumab 160 mg every 4 weeks.1
Rapid responses to the therapy were evident for the primary endpoint, ASAS40 at week 16, with a notable separation from placebo observed after the initial dose, the study stated. Both trials met the primary endpoint with statistical significance (P < .001). The proportion of patients initially randomized to the intervention group achieving response was consistently maintained from week 16 to week 52, indicating sustained efficacy over time in both nr-axSpA and radiographic r-axSpA axSpA.
Analysis of ASAS40 responses at week 16 revealed sustained efficacy of bimekizumab up to week 52, irrespective of patients' prior exposure to tumor necrosis factor inhibitors (TNFi). Patients who were TNFi-naïve and TNFi-inadequate responder (TNFi-IR) exhibited sustained ASAS40 responses from week 16 to week 52, with only slight variations observed in certain subgroups.
The study assessed additional secondary endpoints, including ASAS20 and ASAS partial remission (ASAS PR), which also showed significant improvements with bimekizumab compared with placebo at week 16. These improvements were sustained through week 52 among patients initially randomized to the intervention, while patients switching from placebo to intervention exhibited progressive improvements over time, eventually reaching similar levels to those of bimekizumab-randomized patients by the end of the study.
The BE MOBILE trials' findings suggest that bimekizumab is an effective treatment option, offering sustained efficacy across the entire disease spectrum of axSpA, investigators noted. The ongoing open-label extension trial, BE MOVING, will continue to evaluate the long-term efficacy and safety of bimekizumab up to 3 years of treatment, potentially providing further insights into its role in axSpA management and influencing future treatment guidelines and policies.
References
1. Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83(2):199-213. doi:10.1136/ard-2023-224803
2. Joszt L. Indirect comparison finds bimekizumab more effective than guselkumab in psoriatic arthritis. AJMC®. Published April 4, 2024. https://www.ajmc.com/view/indirect-comparison-finds-bimekizumab-more-effective-than-guselkumab-in-psoriatic-arthritis
ATS 2024 Data Support Triple Therapy FF/UMEC/VI as Preferred Option for COPD
May 21st 2024New data reveal that starting furoate/umeclidinium/vilanterol (FF/UMEC/VI) without delay not only significantly reduces exacerbations and health care costs but also enhances adherence and persistence for patients with chronic obstructive pulmonary disease (COPD) compared with other therapies.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
May 21st 2024A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Read More
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More
Patients With COPD, PRISm at Increased All-Cause, Cause-Specific Mortality Risk
May 20th 2024Patients with chronic obstructive pulmonary disease (COPD) and/or preserved ratio impaired spirometry (PRISm) have an increased risk of all-cause and cause-specific mortality, highlighting the need for better understanding of these conditions through increased spirometry data collection.
Read More